From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling
Virtual patients and digital patients/twins are two similar concepts gaining increasing
attention in health care with goals to accelerate drug development and improve patients' …
attention in health care with goals to accelerate drug development and improve patients' …
[HTML][HTML] Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial
Human clinical trials are important tools to advance novel systemic therapies improve
treatment outcomes for cancer patients. The few durable treatment options have led to a …
treatment outcomes for cancer patients. The few durable treatment options have led to a …
Physiological Indirect Response Model to Omics-Powered Quantitative Systems Pharmacology Model
Over the past several decades, mathematical modeling has been applied to increasingly
wider scopes of questions in drug development. Accordingly, the range of modeling tools …
wider scopes of questions in drug development. Accordingly, the range of modeling tools …
Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling
M Schirru, H Charef, KE Ismaili, F Fenneteau… - … of Pharmacokinetics and …, 2024 - Springer
Abstract Non-Small Cell Lung Cancer (NSCLC) remains one of the main causes of cancer
death worldwide. In the urge of finding an effective approach to treat cancer, enormous …
death worldwide. In the urge of finding an effective approach to treat cancer, enormous …
Integration of Clinical Trial Spatial Multi-omics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery
Computational methods that simulate tumors mathematically to describe cellular and
molecular interactions are emerging as promising tools to simulate the impact of therapy …
molecular interactions are emerging as promising tools to simulate the impact of therapy …
Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology
Understanding the intricate interactions of cancer cells with the tumor microenvironment
(TME) is a pre-requisite for the optimization of immunotherapy. Mechanistic models such as …
(TME) is a pre-requisite for the optimization of immunotherapy. Mechanistic models such as …
Quantitative systems pharmacology modeling of macrophage‐targeted therapy combined with PD‐L1 inhibition in advanced NSCLC
Immune checkpoint inhibitors remained the standard‐of‐care treatment for advanced non‐
small cell lung cancer (NSCLC) for the past decade. In unselected patients, anti‐PD‐(L) 1 …
small cell lung cancer (NSCLC) for the past decade. In unselected patients, anti‐PD‐(L) 1 …
Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination …
CY Wang, HR Dai, YP Tan, DH Yang, XM Niu, L Han… - Pharmaceuticals, 2024 - mdpi.com
Immunotherapy has shown clinical benefit in patients with non-small-cell lung cancer
(NSCLC). Due to the limited response of monotherapy, combining immune checkpoint …
(NSCLC). Due to the limited response of monotherapy, combining immune checkpoint …
Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy
C Li, Z Ren, G Yang, J Lei - Bulletin of Mathematical Biology, 2024 - Springer
Bladder cancer poses a significant global health burden with high incidence and recurrence
rates. This study addresses the therapeutic challenges in advanced bladder cancer …
rates. This study addresses the therapeutic challenges in advanced bladder cancer …
Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC
Recently, immunotherapies for antitumoral response have adopted conditionally activated
molecules with the objective of reducing systemic toxicity. Amongst these are conditionally …
molecules with the objective of reducing systemic toxicity. Amongst these are conditionally …